Rachel D Freed1, Cecilia N Hollenhorst1, Nora Weiduschat2, Xiangling Mao2, Guoxin Kang2, Dikoma C Shungu2, Vilma Gabbay3. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA. 3. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA. Electronic address: vilma.gabbay@mssm.edu.
Abstract
AIM: This study used proton magnetic resonance spectroscopy (1H MRS) to measure in vivo brain glutathione (GSH) in adolescents with major depressive disorder (MDD), and explored the relationship between GSH and illness severity and chronicity. Secondarily, associations between GSH and anhedonia, a key symptom of MDD in adolescents, were investigated. METHODS: Occipital cortex GSH levels were obtained in 19 psychotropic medication-free adolescents with MDD (ages 12-21) and compared to those in eight healthy control adolescents. Correlations between GSH levels and anhedonia severity were examined both in the full participant sample and within the MDD group. Within the MDD group, correlations between GSH levels and illness severity and chronicity were assessed. RESULTS: Occipital GSH levels were lower in adolescents with MDD compared to controls, but did not correlate with anhedonia (either within the MDD group or the full sample), MDD severity, or onset. There were also no group differences in levels of total choline, creatine, and N-acetylaspartate - all neurometabolites that were simultaneously detected with 1H MRS. CONCLUSIONS: Although preliminary, findings add new data to support the role of oxidative stress in MDD and suggest that lower GSH may be a potential marker of MDD early on in the course of illness.
AIM: This study used proton magnetic resonance spectroscopy (1HMRS) to measure in vivo brain glutathione (GSH) in adolescents with major depressive disorder (MDD), and explored the relationship between GSH and illness severity and chronicity. Secondarily, associations between GSH and anhedonia, a key symptom of MDD in adolescents, were investigated. METHODS: Occipital cortex GSH levels were obtained in 19 psychotropic medication-free adolescents with MDD (ages 12-21) and compared to those in eight healthy control adolescents. Correlations between GSH levels and anhedonia severity were examined both in the full participant sample and within the MDD group. Within the MDD group, correlations between GSH levels and illness severity and chronicity were assessed. RESULTS: Occipital GSH levels were lower in adolescents with MDD compared to controls, but did not correlate with anhedonia (either within the MDD group or the full sample), MDD severity, or onset. There were also no group differences in levels of total choline, creatine, and N-acetylaspartate - all neurometabolites that were simultaneously detected with 1HMRS. CONCLUSIONS: Although preliminary, findings add new data to support the role of oxidative stress in MDD and suggest that lower GSH may be a potential marker of MDD early on in the course of illness.
Authors: Jennifer Keller; Christina B Young; Elizabeth Kelley; Katherine Prater; Daniel J Levitin; Vinod Menon Journal: J Psychiatr Res Date: 2013-06-19 Impact factor: 4.791
Authors: Joan Rosenbaum Asarnow; Lisa H Jaycox; Naihua Duan; Anne P LaBorde; Margaret M Rea; Lingqi Tang; Martin Anderson; Pamela Murray; Christopher Landon; Beth Tang; Diana P Huizar; Kenneth B Wells Journal: J Adolesc Health Date: 2005-12 Impact factor: 5.012
Authors: Andrew T Drysdale; Logan Grosenick; Jonathan Downar; Katharine Dunlop; Farrokh Mansouri; Yue Meng; Robert N Fetcho; Benjamin Zebley; Desmond J Oathes; Amit Etkin; Alan F Schatzberg; Keith Sudheimer; Jennifer Keller; Helen S Mayberg; Faith M Gunning; George S Alexopoulos; Michael D Fox; Alvaro Pascual-Leone; Henning U Voss; B J Casey; Marc J Dubin; Conor Liston Journal: Nat Med Date: 2016-12-05 Impact factor: 53.440
Authors: Daihui Peng; Elizabeth B Liddle; Sarina J Iwabuchi; Chen Zhang; Zhiguo Wu; Jun Liu; Kaida Jiang; Lin Xu; Peter F Liddle; Lena Palaniyappan; Yiru Fang Journal: Psychiatry Res Date: 2015-03-20 Impact factor: 3.222
Authors: Michael H Bloch; Kaitlyn E Panza; Jon E Grant; Christopher Pittenger; James F Leckman Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-03 Impact factor: 8.829
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: M G Saleh; A Papantoni; M Mikkelsen; S C N Hui; G Oeltzschner; N A Puts; R A E Edden; S Carnell Journal: AJNR Am J Neuroradiol Date: 2020-05-07 Impact factor: 3.825
Authors: Ana Paula Vargas Visentin; Rafael Colombo; Ellen Scotton; Débora Soligo Fracasso; Adriane Ribeiro da Rosa; Catia Santos Branco; Mirian Salvador Journal: Oxid Med Cell Longev Date: 2020-04-14 Impact factor: 6.543
Authors: Cecilia Luz Balderas-Vazquez; Blandina Bernal-Morales; Eliud Alfredo Garcia-Montalvo; Libia Vega; Emma Virginia Herrera-Huerta; Juan Francisco Rodríguez-Landa; José Felipe Velázquez-Hernández; María Del Carmen Xotlanihua-Gervacio; Olga Lidia Valenzuela Journal: Front Psychol Date: 2022-01-05
Authors: Benjamin A Ely; Tram N B Nguyen; Russell H Tobe; Audrey M Walker; Vilma Gabbay Journal: Front Psychiatry Date: 2021-07-23 Impact factor: 4.157